Creative Planning’s Rocket Pharmaceuticals RCKT Stock Holding History

Creative Planning’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$450K	Sell	131,583 -86,268	-40%	-$287K	﹤0.01%	3264
2026 Q1	$780K	Buy	217,851 +50,812	+30%	+$202K	﹤0.01%	2664
2025 Q4	$586K	Buy	167,039 +12,054	+8%	+$41.3K	﹤0.01%	2697
2025 Q3	$505K	Buy	154,985 +111,514	+257%	+$351K	﹤0.01%	2709
2025 Q2	$107K	Sell	43,471 -36,130	-45%	-$183K	﹤0.01%	3417
2025 Q1	$531K	Sell	79,601 -9,243	-10%	-$91.3K	﹤0.01%	2227
2024 Q4	$1.12M	Buy	+88,844	New	+$1.34M	﹤0.01%	1563
2017 Q2	–	Sell	-500	Closed	-$4K	–	4794
2017 Q1	$4K	Hold	500	–	–	﹤0.01%	4069
2016 Q4	$12K	Sell	500 -750	-60%	-$21.4K	﹤0.01%	3434
2016 Q3	$47K	Buy	+1,250	New	+$39.3K	﹤0.01%	2412

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Creative Planning's RCKT Position: Q2 2026 in Review

Creative Planning reduced its Rocket Pharmaceuticals (RCKT) stake by 40% in Q2 2026, selling an estimated $287K and leaving 131,583 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #3264.

Creative Planning first reported a position in RCKT in Q3 2016 and has held it in 10 quarters since. The position peaked at $1.12M in Q4 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Creative Planning held 131,583 shares of Rocket Pharmaceuticals worth $450K as of Q2 2026.
Creative Planning sold 86,268 Rocket Pharmaceuticals shares in Q2 2026, an estimated $287K.
Rocket Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3264 holding.
Creative Planning first reported a position in Rocket Pharmaceuticals in Q3 2016 and has held it in 10 quarters since.
Creative Planning's Rocket Pharmaceuticals position peaked at $1.12M in Q4 2024.
180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.